Corrigendum to “Design, synthesis and evaluation of carbamate-bridged amino acid prodrugs of cycloicaritin with improved antitumor activity, aqueous solubility and phase II metabolic stability” [Eur. J. Med. Chem. 276 (2024) 116646]

IF 6 2区医学 Q1 CHEMISTRY, MEDICINAL

European Journal of Medicinal Chemistry Pub Date : 2025-04-06 DOI:10.1016/j.ejmech.2025.117594

Weiping Wang, Jiaqi Fan, Fengxiao Li, Shuo Gan, Jiaming Zhang, Yanfang Wang, Yingchao Li, Wenchao Li, Zhonggui He, Huaiwei Ding, Yongbing Sun, Tianhong Zhang, Qikun Jiang

引用次数: 0

Abstract

The authors regret an error in Acknowledgments. The corrected version is provided below:

查看原文本刊更多论文

“设计、合成和评价氨基甲酸酯桥接氨基酸环虫苷前药，提高抗肿瘤活性、水溶性和II期代谢稳定性”的更正[欧洲]。J. Med. Chem. 276 (2024) 116646]

作者对致谢中的错误表示遗憾。更正后的版本如下：

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Medicinal Chemistry 化学-医药化学

CiteScore

11.70

自引率

9.00%

发文量

863

审稿时长

29 days

期刊介绍： The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.